Article
Oncology
A. Bardia, S. M. Tolaney, K. Punie, D. Loirat, M. Oliveira, K. Kalinsky, A. Zelnak, P. Aftimos, F. Dalenc, S. Sardesai, E. Hamilton, P. Sharma, S. Recalde, E. C. Gil, T. Traina, J. O'Shaughnessy, J. Cortes, M. Tsai, L. Vahdat, V Dieras, L. A. Carey, H. S. Rugo, D. M. Goldenberg, Q. Hong, M. Olivo, L. M. Itri, S. A. Hurvitz
Summary: The biomarker analysis from the ASCENT trial demonstrates that sacituzumab govitecan (SG) provides improved survival outcomes and objective response rates in previously treated mTNBC patients with high/medium Trop-2 expression compared to standard-of-care chemotherapy (TPC), regardless of germline BRCA1/2 mutation status. The efficacy outcomes were consistently higher with SG compared to TPC in patients with both high/medium Trop-2 expression and those without germline BRCA1/2 mutations.
ANNALS OF ONCOLOGY
(2021)
Article
Oncology
Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Veronique Dieras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortes
Summary: Sacituzumab govitecan (SG) improves progression-free survival and overall survival in patients with metastatic triple-negative breast cancer (mTNBC), with manageable safety profile.
Article
Oncology
Sibylle Loibl, Delphine Loirat, Sara M. Tolaney, Kevin Punie, Mafalda Oliveira, Hope S. Rugo, Aditya Bardia, Sara A. Hurvitz, Adam M. Brufsky, Kevin Kalinsky, Javier Cortes, Joyce A. O'Shaughnessy, Veronique Dieras, Lisa A. Carey, Luca Gianni, Mahdi Gharaibeh, Luciana Preger, See Phan, Lawrence Chang, Ling Shi, Martine J. Piccart
Summary: This study investigated the effect of the antibody-drug conjugate sacituzumab govitecan (SG) on the health-related quality of life (HRQoL) in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that SG was associated with greater improvements and delayed worsening of HRQoL scores compared with other treatment options chosen by physicians.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Laura M. Spring, Erika Nakajima, Jennifer Hutchinson, Elene Viscosi, Gayle Blouin, Colin Weekes, Hope Rugo, Beverly Moy, Aditya Bardia
Summary: Patients with metastatic triple-negative breast cancer have a poor prognosis. Sacituzumab govitecan has shown promising therapeutic activity and received accelerated approval for the treatment of these patients. Limited information is available regarding adverse event management with this agent.
Article
Oncology
Timothee Olivier, Vinay Prasad
Summary: The ASCENT trial demonstrated improved overall survival in metastatic TNBC patients with sacituzumab govitecan compared to single-agent chemotherapy, but the trial design features may introduce biases and raise concerns about the generalizability of the results to real-world settings. Open-label design, choice of PFS as primary endpoint, restricted control arm, and differences in dose recommendations for experimental drug all have the potential to favor the experimental arm or penalize the control arm.
TRANSLATIONAL ONCOLOGY
(2022)
Article
Oncology
Anna R. Schreiber, Michelle Andress, Jennifer R. Diamond
Summary: Sacituzumab govitecan has demonstrated promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial. Common adverse effects include neutropenia, diarrhea, and nausea, which are manageable with supportive care. In addition to TNBC, Sacituzumab govitecan has shown potential in cancers such as urothelial and lung, and is being studied in HR-positive breast cancers. The therapy is likely to be used in combination with other novel targeted agents as ongoing clinical trials progress.
EXPERT REVIEW OF ANTICANCER THERAPY
(2021)
Article
Oncology
Yitian Lang, Qingqing Chai, Wenqi Tao, Yahui Liao, Xiaoyan Liu, Bin Wu
Summary: The ASCENT trial demonstrated the efficacy of sacituzumab govitecan for the treatment of advanced or metastatic triple-negative breast cancer (TNBC). The study evaluated the cost-effectiveness of receiving sacituzumab govitecan compared with standard chemotherapy from the United States payer perspective. The cost-effectiveness analysis suggests that sacituzumab govitecan, at the current price, is unlikely to be the preferred option for patients with advanced or metastatic TNBC from a US payer's point of view at a threshold of $150,000/QALY.
Article
Medicine, General & Internal
Shao-Xian Cheng, Qiu-Chi Chen, Guo-He Lin, Yan-Hong Han, Bi-Cheng Wang, Yi Dai, Yan-Xia Zhao
Summary: This study evaluated the efficacy and safety of Sacituzumab govitecan (SG) in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC). The results showed that SG had a certain effectiveness in these patients, and the main treatment-related adverse events were myelosuppression and diarrhea.
Article
Oncology
Aditya Bardia, Sara A. Hurvitz, Hope S. Rugo, Adam Brufsky, Javier Cortes, Sibylle Loibl, M. Piccart, Janice Cowden, Patty Spears, Lisa A. Carey
Summary: Sacituzumab Govitecan, a new treatment for metastatic triple-negative breast cancer, has shown in the ASCENT study to provide better survival and tumor shrinkage effects for mTNBC patients, although it also comes with more side effects.
Article
Oncology
Sakar Wahby, Lola Fashoyin-Aje, Christy L. Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Summary: FDA granted accelerated approval to Sacituzumab Govitecan-hziy for the treatment of metastatic triple-negative breast cancer. Data showed an objective response rate of 33.3% and a median duration of response of 7.7 months, supporting the approval.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Joyce O'Shaughnessy, Adam Brufsky, Hope S. Rugo, Sara M. Tolaney, Kevin Punie, Sagar Sardesai, Erika Hamilton, Delphine Loirat, Tiffany Traina, Roberto Leon-Ferre, Sara A. Hurvitz, Kevin Kalinsky, Aditya Bardia, Stephanie Henry, Ingrid Mayer, Yanni Zhu, See Phan, Javier Cortes
Summary: This study analyzed the efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer (mTNBC). The results showed that regardless of whether patients had TNBC at initial diagnosis, sacituzumab govitecan improved clinical outcomes. For patients without TNBC at initial diagnosis, the clinical efficacy and safety of sacituzumab govitecan were manageable.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Jigang Chen, Mingyang Han, Aihua Liu, Bo Shi
Summary: The study evaluated the cost-effectiveness of Sacituzumab Govitecan for metastatic triple-negative breast cancer from the perspectives of China and the United States. Results showed that the current price of SG is unlikely to be cost-effective in both countries. Sensitivity analysis indicated that the price of SG has the greatest impact on cost-effectiveness.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Binghe Xu, Fei Ma, Tao Wang, Shusen Wang, Zhongsheng Tong, Wei Li, Xinhong Wu, Xiaojia Wang, Tao Sun, Yueyin Pan, Herui Yao, Xian Wang, Ting Luo, Jin Yang, Xiaohua Zeng, Weihong Zhao, Xiuyu Julie Cong, Jiongjie Chen
Summary: This is the first report on the efficacy and safety of Sacituzumab govitecan in Chinese patients with mTNBC. The study found that Sacituzumab govitecan demonstrated substantial clinical activity in heavily pretreated Chinese patients with mTNBC and had a manageable safety profile.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Pierluigi di Mauro, Greta Schivardi, Rebecca Pedersini, Lara Laini, Andrea Esposito, Vito Amoroso, Marta Lagana, Salvatore Grisanti, Deborah Cosentini, Alfredo Berruti
Summary: This article reports a case of a TNBC patient who achieved significant results after receiving sacituzumab govitecan treatment. This treatment can improve the survival rate of early recurrent and BRCA-mutant TNBC patients.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
S. Michaleas, A. Moreno Oliver, J. Mueller-Berghaus, S. B. Sarac, M. E. van der Elst, S. Mueller-Egert, H. Zander, H. Enzmann, F. Pignatti
Summary: Sacituzumab govitecan (SG) is an antineoplastic agent approved as a monotherapy for the treatment of unresectable or metastatic triple-negative breast cancer (mTNBC). SG combines a humanized monoclonal antibody binding to tropoblast cell surface antigen-2 (Trop-2)-expressing cancer cells with a cytotoxic moiety SN-38 (govitecan) that acts as a topoisomerase I inhibitor. A phase III trial showed statistically significant improvements in progression-free survival (PFS) and overall survival (OS) with SG compared to treatment of physician's choice (TPC) in patients with mTNBC. Common side effects of SG include diarrhea, neutropenia, nausea, fatigue, alopecia, anemia, constipation, and vomiting.
Article
Oncology
K. H. J. Lim, K. Murali, E. Thorne, K. Punie, K. Kamposioras, C. Oing, M. O'Connor, E. Elez, T. Amaral, P. Garrido, M. Lambertini, B. Devnani, C. B. Westphalen, G. Morgan, J. B. A. G. Haanen, C. Hardy, S. Banerjee
Summary: COVID-19 has significantly impacted the well-being and job performance of oncology professionals globally. Despite improved job performance, there is still a high risk of poor well-being, distress, and burnout among oncology professionals. They are also facing issues of overwhelming workload and concerns about career development, job security, and international fellowship opportunities.
Letter
Oncology
F. Poggio, M. Tagliamento, M. Ceppi, M. Bruzzone, B. Conte, P. Fregatti, K. Punie, E. de Azambuja, L. Del Mastro, M. Lambertini
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Andrea Aran, Laia Garrigos, Giuseppe Curigliano, Javier Cortes, Merce Marti
Summary: The study of TCR repertoire in cancer patients is important for understanding the anti-tumoural response, predicting prognosis, and determining response to immune checkpoint inhibitor therapies. The TCR repertoire is influenced by various factors and can provide valuable insights for modulating immune responses and predicting outcomes.
Article
Oncology
Simona Bruzas, Oleg Gluz, Nadia Harbeck, Peter Schmid, Javier Cortes, Jens Blohmer, Christine Seiberling, Ouafaa Chiari, Hakima Harrach, Beyhan Ataseven, Satyendra Shenoy, Mark H. Dyson, Eugen Traut, Ingo Theuerkauf, Daniel Gebauer, Sherko Kuemmel, Mattea Reinisch
Summary: A significant number of early breast cancer patients experience relapse after neoadjuvant therapy, even if the tumors achieved pathologic complete response (pCR). Gene expression analysis revealed that recurrent tumors had lower expression of estrogen receptor signaling and immune-related expression parameters compared to primary tumors. Interindividual analysis showed that patients with any relapse or distant relapse had lower expression of major histocompatibility complex class II in their primary tumors. Additionally, primary tumors with later distant relapse had higher homologous recombination deficiency. Although these associations did not remain statistically significant after adjusting for false discovery rate, our findings suggest that transcriptomic analysis has potential prognostic value for early breast cancer patients at risk of relapse and should be further investigated.
Review
Oncology
Diogo Martins-Branco, Guilherme Nader-Marta, Ana Tecic Vuger, Veronique Debien, Lieveke Ameye, Mariana Brandao, Kevin Punie, Angela Loizidou, Karen Willard-Gallo, Chloe Spilleboudt, Ahmad Awada, Martine Piccart, Evandro de Azambuja
Summary: This systematic review and meta-analysis evaluated the immune response to anti-SARS-CoV-2 vaccination in cancer patients. The results showed that cancer patients had sustained humoral and adaptive immune responses for at least 2 months after complete prime-vaccination. However, patients with hematological malignancies had lower immune responses.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Kala Visvanathan, Leslie Cope, Mary Jo Fackler, Michael Considine, Lori Sokoll, Lisa A. Carey, Andres Forero-Torres, James N. Ingle, Nancy U. Lin, Rita Nanda, Anna Maria Storniolo, Suzana Tulac, Neesha Venkatesan, Natalie C. Wu, Sudhakar Marla, Scott Campbell, Michael Bates, Christopher B. Umbricht, Antonio C. Wolff, Saraswati Sukumar
Summary: This study evaluated the clinical utility of a novel liquid biopsy-breast cancer methylation (LBx-BCM) prototype assay for early assessment of disease progression in women with metastatic breast cancer (MBC). The results showed that high levels of cumulative methylation (CM) were associated with shorter median progression-free survival (PFS) and overall survival (OS) at week 4. The CM levels at week 4 could be used to predict disease progression as early as 3 months after initiating a new treatment.
CLINICAL CANCER RESEARCH
(2023)
Editorial Material
Oncology
Beverly Moy, R. Bryan Rumble, Lisa A. Carey
Summary: ASCO Rapid Recommendations Updates are revisions to specific ASCO guideline recommendations based on new and practice-changing data. These updates are supported by evidence review and follow ASCO's guideline development processes. The articles aim to disseminate updated recommendations in a timely manner to inform healthcare practitioners and the public about the best available cancer care options.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hope S. Rugo, Seock-Ah Im, Fatima Cardoso, Javier Cortes, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escriva-de-Romani, Michelino De Laurentiis, Gary N. Schwartz, Timothy J. Pluard, Francesco Ricci, William R. Gwin II, Christelle Levy, Ursa Brown-Glaberman, Jean-Marc Ferrero, Maaike de Boer, Sung-Bae Kim, Katarina Petrakova, Denise A. Yardley, Orit Freedman, Erik H. Jakobsen, Einav Nili Gal-Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar
Summary: Clinical trials often report initial results based on the primary end point, while additional results from secondary analyses may not be available. In this study comparing margetuximab and trastuzumab in breast cancer patients, the final overall survival analysis did not show an advantage of margetuximab over trastuzumab. However, exploratory analysis suggested potential improvements in specific patient groups based on CD16A genotyping.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Cristina Saavedra, Maria Gion, Javier Cortes, Antonio Llombart-Cussac
Summary: Despite advancements in precision medicine for breast cancer, more research is needed to improve cure rates for early-stage patients and extend survival with optimal quality of life for those with metastatic disease. Major progress was made last year, thanks to the significant impact of immunotherapy on survival in triple-negative breast cancer and the promising results of antibody-drug conjugates.
Review
Oncology
Maximilian J. Mair, Rupert Bartsch, Emilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortes, Hui K. Gan, Nancy U. Lin, Andrew B. Lassman, Patrick Y. Wen, Michael Weller, Martin van den Bent, Matthias Preusser
Summary: Antibody-drug conjugates (ADCs) have shown efficacy in various cancers, but their activity in the central nervous system (CNS) may be limited by the blood-brain barrier. This review summarizes the available clinical data on ADCs against primary and secondary brain tumors and ongoing trials. It also discusses the physical, biological, and molecular determinants of ADCs' CNS activity and potential strategies to improve drug delivery to brain tumors.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortes, Henry L. Gomez Moreno, Xichun Hu, Komal Jhaveri, Petr Krivorotko, Sibylle Loibl, Serafin Morales Murillo, Meena Okera, Yeon Hee Park, Joohyuk Sohn, Masakazu Toi, Eriko Tokunaga, Samih Yousef, Lyudmila Zhukova, Elza C. de Bruin, Lynda Grinsted, Gaia Schiavon, Andrew Foxley, Hope S. Rugo
Summary: Capivasertib-fulvestrant therapy significantly improves progression-free survival in patients with hormone receptor-positive advanced breast cancer, particularly those with AKT pathway alterations.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Helene Francois-Martin, Audrey Lardy-Cleaud, Barbara Pistilli, Christelle Levy, Veronique Dieras, Jean-Sebastien Frenel, Severine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule Augereau, Thomas Bachelot, Lionel Uwer, Marc Debled, Jean-Marc Ferrero, Florian Clatot, Anthony Goncalves, Michael Chevrot, Sylvie Chabaud, Paul Cottu
Summary: This study evaluated the impact of everolimus-based therapy on overall survival in a national cohort of breast cancer patients. The findings suggest that everolimus may improve overall survival in advanced hormone receptor positive, HER2 negative breast cancer, but its usage is currently underutilized in clinical practice.
Article
Oncology
Beverly Moy, Antonio C. Wolff, R. Bryan Rumble, Kimberly H. Allison, Lisa A. Carey
JCO ONCOLOGY PRACTICE
(2023)
Article
Multidisciplinary Sciences
Ha-Linh Nguyen, Tatjana Geukens, Marion Maetens, Samuel Aparicio, Ayse Bassez, Ake Borg, Jane Brock, Annegien Broeks, Carlos Caldas, Fatima Cardoso, Maxim De Schepper, Mauro Delorenzi, Caroline A. Drukker, Annuska M. Glas, Andrew R. Green, Edoardo Isnaldi, Jorunn Eyfjoro, Hazem Khout, Stian Knappskog, Savitri Krishnamurthy, Sunil R. Lakhani, Anita Langerod, John W. M. Martens, Amy E. McCart Reed, Leigh Murphy, Stefan Naulaerts, Serena Nik-Zainal, Ines Nevelsteen, Patrick Neven, Martine Piccart, Coralie Poncet, Kevin Punie, Colin Purdie, Emad A. Rakha, Andrea Richardson, Emiel Rutgers, Anne Vincent-Salomon, Peter T. Simpson, Marjanka K. Schmidt, Christos Sotiriou, Paul N. Span, Kiat Tee Benita Tan, Alastair Thompson, Stefania Tommasi, Karen Van Baelen, Marc Van de Vijver, Steven Van Laere, Laura van't Veer, Giuseppe Viale, Alain Viari, Hanne Vos, Anke T. Witteveen, Hans Wildiers, Giuseppe Floris, Abhishek D. Garg, Ann Smeets, Diether Lambrechts, Elia Biganzoli, Francois Richard, Christine Desmedt
Summary: Obesity is associated with an increased risk of developing breast cancer and worse prognosis in breast cancer patients. This study investigates the biological differences in untreated primary breast cancer according to patients' body mass index (BMI). The study finds several genomic alterations that are differentially prevalent in overweight or obese patients compared to lean patients. It also reveals an elevated and unresolved inflammation of the breast cancer tumor microenvironment associated with obesity. The findings suggest that patient adiposity may play a significant role in the heterogeneity of breast cancer and should be considered for tailored treatment.
NATURE COMMUNICATIONS
(2023)
Article
Genetics & Heredity
Yentl Lambrechts, Abhishek D. Garg, Giuseppe Floris, Kevin Punie, Patrick Neven, Ines Nevelsteen, Jannes Govaerts, Francois Richard, Annouschka Laenen, Christine Desmedt, Hans Wildiers, Sigrid Hatse
Summary: There is an urgent need for new and improved biomarker modalities to estimate the risk of recurrence in breast cancer patients. This study provides proof of concept that various liquid biopsy read-outs could be used to build a multi-modal biomarker model that can distinguish between early metastasizing and non-metastasizing patients.
GENES AND IMMUNITY
(2023)